Evidence map›Paper›PMID 37995469›Full record

ArticleSeminars in arthritis and rheumatism2024

Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.

Paras Karmacharya, Cynthia S Crowson, Ryan J Lennon, Dilli Poudel, John M Davis, Alexis Ogdie, Jean W Liew, Michael M Ward, Mariko Ishimori, Michael H Weisman and 5 more

Open access · greenAbstract read
In one paragraph

Article in Seminars in arthritis and rheumatism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Paras KarmacharyaVanderbilt University Medical Center, Division of Rheumatology & Immunology, Nashville, TN, United States of America; Mayo Clinic, Division of Rheumatology, Rochester, MN, United States of America. Electronic address: paraskarmacharya@gmail.com.
Cynthia S CrowsonMayo Clinic, Division of Rheumatology, Rochester, MN, United States of America; Mayo Clinic, Department of Quantitative Health Sciences, Rochester, MN, United States of America.
Ryan J LennonMayo Clinic, Department of Quantitative Health Sciences, Rochester, MN, United States of America.
Dilli PoudelIndiana Regional Medical Center, Indiana, PA, United States of America.
John M DavisMayo Clinic, Division of Rheumatology, Rochester, MN, United States of America.
Alexis OgdiePerelman School of Medicine, University of Pennsylvania, Departments of Medicine/Rheumatology and Biostatistics, Epidemiology and Informatics, Philadelphia, United States of America.
Jean W LiewBoston University Chobanian & Avedisian School of Medicine, Section of Rheumatology, Boston, MA, USA.
Michael M WardNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Intramural Research Program, Bethesda, USA.
Mariko IshimoriCedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, USA.
Michael H WeismanCedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, USA.
Matthew A BrownDepartment of Medical and Molecular Genetics, Faculty of Health, King's College London, England; Genomics England, London, England.
Mohammad H RahbarDivision of Clinical and Translational Sciences, McGovern Medical School, and Biostatistics/Epidemiology/Research Design (BERD) Core, Center for Clinical and Translational Sciences, (CCTS) at the University of Texas Health Science Center at Houston, USA.
Mark C HwangMcGovern Medical School at the University of Texas Health Science Center, Division of Rheumatology and Clinical Immunogenetics, Houston, USA.
John D ReveilleMcGovern Medical School at the University of Texas Health Science Center, Division of Rheumatology and Clinical Immunogenetics, Houston, USA.
Lianne S GenslerUniversity of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, USA.
Mayo Clinic in Arizona · USCedars-Sinai Medical Center · USThe University of Texas Health Science Center at Houston · USBoston University · USKing's College London · GBMayo Clinic in Florida · USNational Institutes of Health · USRegional Medical Center · USUniversity of California, San Francisco · USUniversity of Pennsylvania · US

Funding

The Genetic Basis of AS SusceptibilityP01AR052915 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI REVEILLE, JOHN DUFFIN · 2006 to 2016
$10.9M
Association of Phenotypes and Genotype with Treatment Response in Psoriatic ArthritisK23AR082990 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paras Karmacharya · 2023 to 2026
$654k
NIAMS NIH HHS K23 AR082990NIAMS NIH HHS P01 AR052915
6 · The paper itself

Abstract

objectivesTo examine the association of multimorbidity phenotypes at baseline with disease activity and functional status over time in ankylosing spondylitis (AS).

methodsPatient-reported AS morbidities (comorbidities, N = 28 and extra-musculoskeletal manifestations, EMMs, N = 3) within 3 years of enrollment with a prevalence ≥1 %, were included from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort. We defined multimorbidity as ≥2 morbidities (MM2+) and substantial multimorbidity as ≥5 morbidities (MM5+). Multimorbidity clusters or phenotypes were identified using K-median clustering. Disease activity (ASDAS-CRP) and functional status (BASFI) measures were collected every 6 months. Generalized estimating equation method was used to examine the associations of multimorbidity counts and multimorbidity clusters with measures of disease activity and functional status over time.

resultsAmong 1,270 AS patients (9,885 visits) with a median follow-up of 2.9 years (IQ range: 1.0-6.8 years), the prevalence of MM2+ and MM5+ was 49 % and 9 % respectively. We identified five multimorbidity clusters: depression (n = 321, 25 %), hypertension (n = 284, 22 %), uveitis (n = 274, 22 %), no morbidities (n = 238, 19 %), and miscellaneous (n = 153, 12 %). Patients in the depression cluster were more likely to be female and had significantly more morbidities and worse disease activity and functional status compared to those with no morbidities.

conclusionApproximately 49 % of AS patients in the PSOAS cohort had multimorbidity and five distinct multimorbidity phenotypes were identified. In addition to the number of morbidities, the type of morbidity appears to be important to longitudinal outcomes in AS. The depression cluster was associated with worse disease activity and function.

Indexed as

Spondylitis, AnkylosingComorbidityFemaleHumansMaleMultimorbidityPhenotypeProspective StudiesSeverity of Illness IndexAnkylosing spondylitisDisease activityFunctionMultimorbiditySpondyloarthritis

Identifiers

PMID37995469
PMCPMC10872589
OpenAlexW4388440477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.